.png){kind=icon}
.png){kind=icon}
Return
Sodium zirconium cyclosilicate (Lokelma) to enable ACEIs/ARBs use in the treatment of patients with diabetic kidney disease
.png){kind=icon}
PRE
AI
H
J
L
X
N
Y
C
Y
G
Z
J
R
王
DOI：10.1016/j.diabres.2025.112413.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
In diabetic kidney disease (DKD), Angiotensin-converting enzyme inhibitors (ACEIs)/ angiotensin receptor blockers (ARBs) are key treatments but may cause hyperkalemia. This randomized controlled trial (RCT) firstly evaluates sodium zirconium cyclosilicate (SZC) to optimize renin-angiotensin-aldosterone system inhibitor (RAASi) use in DKD, addressing evidence gaps in this field.
Keywords:
diabetic kidney disease
ACEIs/ARBs
hyperkalemia
sodium zirconium cyclosilicate
RAASi optimization
Journal
IF:
7.4
Papers:
1.1W
Citations:
2.2W
Organization
Cited Papers